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dependently of this physiological phenomenon. For this 
patient group, both endobronchial coils  [7, 8] as well as 
sclerosing therapies  [9–11] have shown potential as treat-
ment options. Collateral ventilation thus seems the most 
important denominator in both chronic obstructive pul-
monary disease and in bronchoscopic lung volume re-
duction. Where there is a dominant chronic obstructive 
pulmonary disease component, there is mucosal inflam-
mation, bronchospasm, irregular airways, and mucus 
plugging. In this situation, the resistance of the airways is 
usually high leading to progressive air trapping, hypox-
emia and hypercapnia. With progressive emphysema, 
there is destruction of the alveolar parenchyma increas-
ing both intra- and interlobar collateral ventilation. Very 
early studies in excised emphysematous lungs confirmed 
that the resistance to collateral flow is much lower than 
the resistance in the airways  [12] . This allows the ex-
change of gas even in obstructed segments and may ac-
count for the relative preservation of hypoxemia in em-
physema patients.
 In the past, several attempts have been made to take 
advantage of the abundant presence of collateral ventila-
tion in severe emphysema by creating fenestrations – a 
so-called “airway bypass” – between the areas of trapped 
air and places where this air can easily be released. Early 
 Over the past decade, significant improvements have 
been made in developing nonpharmacological interven-
tions to enhance lung mechanics in patients with severe 
emphysema  [1] . Collateral ventilation has been an influ-
ential factor for some of the therapies and is defined as 
ventilation of the alveoli via pathways that bypass the nor-
mal bronchial airways. The initial randomized controlled 
trials with endobronchial valves failed to demonstrate 
clinically meaningful results as a proportion of the treated 
patients had collateral ventilation and hence did not de-
velop lobar atelectasis  [2] . Once the role of collateral ven-
tilation was appreciated and patients were more carefully 
selected on the basis of formal measurements, remarkable 
benefits have been observed with mean improvements in 
FEV 1 between 20 and 25%  [3–5] . Such is the importance 
of collateral ventilation that surrogate markers for collat-
eral ventilation such as fissure integrity are formally as-
sessed on the computed tomography scans at the screen-
ing stage and in the majority of patients formal measure-
ments of collateral ventilation are performed by the 
Chartis procedure as recommended by the latest Best 
Practice Guidelines  [6] .
 A significant proportion of patients with emphysema 
have collateral ventilation and hence alternative bron-
choscopic techniques have been developed that work in-
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work in this field both showed potential using a transtho-
racic airway bypass approach  [13, 14] , as well as creating 
a bronchoscopic transbronchial airway bypass  [15] .
 To prove the safety and efficacy of creating extra-ana-
tomic airway bypasses between the most diseased areas of 
the lung and the large airways which were supported by 
paclitaxel drug-eluting stents to ensure patency, a ran-
domized, full sham-controlled, multicenter trial (the 
EASE trial) was performed in patients with severe homo-
geneous emphysema  [16] . The EASE trial showed that the 
airway bypass improved patient outcomes directly after 
the procedure; however, the durability of the effects was 
limited, and outcomes for both the sham-controlled and 
treatment groups were similar long after the procedure. 
Although the concept of creating an airway bypass was 
proven in this trial, the loss of airway bypass patency due 
to several factors caused the loss of the observed initial 
benefit  [16] .
 In this issue of  Respiration , Snell et al.  [17] report on a 
unique treatment in a unique patient population whom 
they were able to follow for years after treatment with a 
transthoracic airway bypass. Creating a transthoracic air-
way bypass comes with a number of potential issues, such 
as thoracic surgery to create the bypass, with initially sig-
nificant subcutaneous emphysema, frequent change of 
the bypass tubing, frequent interventions to clear out the 
bypass channel and of course also local esthetical issues. 
However, this paper again shows the great potential of 
creating functional collateral channels allowing emphy-
sematous lungs to more easily empty and by those means 
improve their dyspnea symptoms. Based on this long-
term follow-up, earlier reports, and our own observations 
 [16, 18] , we can only encourage further innovation and 
development of – preferably endoscopic – techniques 
that will allow this therapeutic approach to become more 
widely applicable for our highly symptomatic severe em-
physema patients. Especially homogeneous emphysema 
patients with a high level of tissue destruction and who do 
have interlobar collateral ventilation seem to be the target 
patients for this therapy.
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